Key clinical point: PD-L1 positive status in the tumor and negative status in the thrombus is linked to aggressive behavior in clear cell renal cell carcinoma.
Major finding: PD-L1 immunostaining was positive in at least one of the three samples of the main tumor in 22 of 39 advanced clear cell renal cell carcinomas. Cases that lost PD-L1 positivity in the thrombus (18 cases), were of higher grade (Fisher's exact test, P = 0.01) and higher AJCC pT category (Cochran Armitage, P = 0.02) than the cases that were positive both in tumor and thrombus (4 cases). A high variability in PD-L1 positivity was noted across three different areas of the main tumor tested. This variability should be kept in mind when selecting the tumor samples to be tested for determining immunotherapy.
Study details: An analysis of PD-L1 (SP142) expression in three different areas of the tumor and in two areas of the renal vein/caval thrombi in 39 advanced clear cell renal cell carcinomas.
Disclosures: The researchers reported no relevant financial disclosures.
Source: Lopez J et al. Annals of Diagnostic Pathology June 2018, Pages 89-93 https://doi.org/10.1016/j.anndiagpath.2018.03.007
Lopez J et al. Annals of Diagnostic Pathology June 2018, Pages 89-93 https://doi.org/10.1016/j.anndiagpath.2018.03.007
This Week's Must Reads
Federal guidelines clearinghouse to shutdown July 16, 2018, www.guidelines.gov
CMS freezing of risk adjustment payments predicted to drive up insurance premiums, United States District Court Ruling Puts Risk Adjustment On Hold
If confirmed as Supreme Court justice, Kavanaugh could upend ACA, Case references, including Seven-Sky v. Holder
Software boosts accuracy of colonoscopies, Tripathi PV et al. DDW 2018 (Digestive Disease Week, 2018). Presentation 133.
Proposed fee schedule for 2019 could cut EHR hours, https://s3.amazonaws.com/public-inspection.federalregister.gov/2018-14985.pdf
Must Reads in Renal Cell Carcinoma
EBUS-TBNA guides need for further treatment in RCC, Val-Bernal J et al. Pathology Research and Practice 2018; 214 (7), 949-56.
Clear cell papillary RCC distinguished by unique staining pattern, Wang Y et al. Annals of Diagnostic Pathology 36: 2018; 1-4. https://doi.org/10.1016/j.anndiagpath.2018.06.007
Myelodysplasia risk high in RCC patients, Shenoy N et al. Clinical Genitourinary Cancer, Published online June 28, 2018. https://doi.org/10.1016/j.clgc.2018.06.008
Pembrolizumab in advanced clear cell RCC, McDermott DF et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 4500.
Do docetaxel nanoparticles boost response in mCRPC?, Autio KA et al. JAMA Oncol. 2018 July 5. doi: 10.1001/jamaoncol.2018.2168.